Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: an R&D division developing therapeutics for inflammation and immunology indications, and a contract development and manufacturing organization (CDMO) providing integrated services to early-stage biotech companies across multiple modalities including biologics and small molecules. The R&D pipeline centers on PC111, a fully human monoclonal antibody targeting soluble Fas ligand for severe dermatological conditions with unmet medical needs, and the NanoAbs platform—nanosized antibody fragments derived from camelid animals—targeting pathways in psoriasis and inflammatory diseases. The company generates revenue from CDMO services delivered through cGMP-certified manufacturing facilities in Israel, while advancing R&D programs through non-dilutive funding and partnerships, with the dual model designed to create operational flexibility and fund pipeline development through external manufacturing revenues.
| USD millions | FY2025 |
|---|---|
| Revenue | 1 |
| Net Income | -8 |